Close-up of stethoscope on desk with doctor's hands using laptop. The female doctor is sitting at desk in office. The focus is on stethoscope.
Our Work

Latham & Watkins Advises Arcutis Biotherapeutics in US$225 Million Non-Dilutive Debt Financing

January 18, 2022
A multidisciplinary deal team represents the late-stage biopharmaceutical company in obtaining a term loan facility from funds managed by SLR Capital Partners.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that it has obtained a US$225 million term loan facility from funds managed by SLR Capital Partners (SLR).

Latham & Watkins LLP represents Arcutis with a transactional team led by Bay Area finance partner Haim Zaltzman, with associates Ramin Montazeri and Hyunji Lee. Advice was also provided on corporate matters by Bay Area partner Brian Cuneo, with associate Ross McAloon; on public company financing matters by New York partner Reza Mojtabaee-Zamani, with associate Eric Rice; on regulatory matters by Washington, D.C. partner Ben Haas and Bay Area counsel Betty Pang, with associate Chad Jennings; on intellectual property matters by Bay Area partner Chris Hazuka; and on tax matters by Bay Area partner Grace Lee, with associate Derek Gumm.

    Related Capabilities